Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB-718 in Healthy Subjects
NCT05021666Phase 1Completed
- Sponsor
- PegBio
- Start
- Jul 2020
- Primary completion
- May 2022
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PB-718 (10 arms), sponsored by PegBio. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 11 weeks. Started Jul 2020; status: completed.
02
Drugs
PB-718
Beyond the preview
Go deeper on NCT05021666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021666.